Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2293 Results for "
NF-
" in MedChemExpress (MCE) Product Catalog:
Products (2293)
2293 Results for "NF-" in MCE Product Catalog:
Cat. No.: HY-113402B
Synonyms: γ-Glu-Cys ammonium
Target:
Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Gamma-glutamylcysteine ammonium (γ-Glu-Cys ammonium) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine ammonium activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine ammonium regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine ammonium is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .
Cat. No.: HY-113402R
CAS No.: 636-58-8
Synonyms: γ-Glu-Cys (Standard)
Synonyms: (9S,13R)-12-OPDA
Cat. No.: HY-P990252
Target:
Research Areas:
Cat. No.: HY-W097625R
CAS No.: 26964-24-9
Cat. No.: HY-W592871R
CAS No.: 765-01-5
Synonyms: 10-HDA (Standard); Queen Bee Acid (Standard)
Category:
Target:
Cat. No.: HY-L074
3,404 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
Cat. No.: HY-165613
CAS No.: 656831-18-4
Synonyms: Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine
Research Areas:
Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection .
Cat. No.: HY-N16637
CAS No.: 408324-05-0
Cat. No.: HY-P7S0254
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: IKBKB; IKK-2; Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta; CDNA FLJ33978 Fis, Clone DFNES2004354, Highly Similar To Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta; IKK-Beta; Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Beta, Isoform CRA_a; NFKBIKB; Nuclear Factor Kappa B Kinase Subunit Beta; IKK2; IkappaB Kinase; IKKB; IKBKB Protein; Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Beta; IMD15A; Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta; IMD15B; Serine/Threonine Protein Kinase IKBKB; IMD15; I-Kappa-B Kinase 2; IkBKB; Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Beta; IKK-B; I-Kappa-B-Kinase Beta
Species:
Human
Source:
HEK293
Cat. No.: HY-P706059
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: IKBKB; IKK-2; Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta; CDNA FLJ33978 Fis, Clone DFNES2004354, Highly Similar To Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta; IKK-Beta; Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Beta, Isoform CRA_a; NFKBIKB; Nuclear Factor Kappa B Kinase Subunit Beta; IKK2; IkappaB Kinase; IKKB; IKBKB Protein; Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Beta; IMD15A; Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta; IMD15B; Serine/Threonine Protein Kinase IKBKB; IMD15; I-Kappa-B Kinase 2; IkBKB; Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Beta; IKK-B; I-Kappa-B-Kinase Beta
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-118828AS
CAS No.: 2692624-08-9
Synonyms: (9S,13R)-12-OPDA-d5
Target:
Isotope-Labeled Compounds Lipoxygenase PGE synthase Keap1-Nrf2 IKK NF-κB NO Synthase Interleukin Related
Research Areas:
(9S,13R)-12-Oxo phytodienoic acid-d5 ((9S,13R)-12-OPDA-d5) is the deuterated-labeled (9S,13R)-12-Oxo phytodienoic acid (HY-118828A). (9S,13R)-12-Oxo phytodienoic acid ((9S,13R)-12-OPDA) is a mPGES-1 inhibitor and Nrf2 activator. (9S,13R)-12-Oxo phytodienoic acid selectively inhibits mPGES-1 expression and reduces inducible PGE2 production without affecting COX-1 or COX-2. (9S,13R)-12-Oxo phytodienoic acid inhibits the phosphorylation of IKKβ, IκBα, and NF-κB (p65), blocks the nuclear translocation of p65, increases the nuclear translocation of Nrf2, and upregulates HO-1 expression. (9S,13R)-12-Oxo phytodienoic acid inhibits the differentiation of M0 macrophages toward the M1 phenotype and promotes differentiation toward the M2 phenotype. (9S,13R)-12-Oxo phytodienoic acid decreases the levels of NO, PGE2, IL-1β, IL-6, iNOS, and PGD2. (9S,13R)-12-Oxo phytodienoic acid can be used for inflammation research .
Cat. No.: HY-P73156
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL12A; Cytotoxic Lymphocyte Maturation Factor 1, P35; Prev. NKSF1; NK Cell Stimulatory Factor Chain 1; IL-12A; Interleukin-12 Alpha Chain; Interleukin-12 Subunit Alpha; Interleukin 12, P35; CLMF; IL-12, Subunit P35; NFSK; IL35 Subunit; P35; CLMF P35; Interleukin 12A (Natural Killer Cell Stimulatory Factor 1, Cytotoxic Lymphocyte Maturation Factor 1, P35); Natural Killer Cell Stimulatory Factor 1, 35 KD Subunit; Cytotoxic Lymphocyte Maturation Factor 35 KDa Subunit; IL-12 Subunit P35; Interleukin 12A; NF Cell Stimulatory Factor Chain 1; IL12B; Interleukin-12 Subunit Beta; Prev. NKSF2; Interleukin 12, P40; IL-12B; IL12, Subunit P40; CLMF2; IL-12 Subunit P40; NKSF; CLMF P40; CLMF; Cytotoxic Lymphocyte Maturation Factor 2, P40; Interleukin 12B (Natural Killer Cell Stimulatory Factor 2, Cytotoxic Lymphocyte Maturation Factor 2, P40); Natural Killer Cell Stimulatory Factor-2; Natural Killer Cell Stimulatory Factor, 40 KD Subunit; Truncated Interleukin 12B; Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit; IMD29; NK Cell Stimulatory Factor Chain 2; IMD28; Interleukin 12B; Interleukin-12 Beta Chain
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
